anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Appropriate prognostic indicators are required for patients with stage IV colorectal cancer (CRC). Lymph node metastasis mainly involves four histological types of CRC. Some metastatic lymph nodes (mLNs) showing cribriform carcinoma are associated with distant metastasis in patients with node-positive CRC and are correlated with recurrence and survival in stage III disease. However, the significance of mLN histology in the prognosis of patients with node-positive stage IV disease remains unclear.
METHODS: We enrolled 449 consecutive patients with CRC who underwent primary tumor resection with lymph node dissection between January 2011 and November 2018. This study included 88 patients with node-positive stage IV CRC and synchronous or metachronous distant metastases. We retrospectively investigated the association between cancer histology in the mLNs based on our classification and cancer-specific survival (CSS) in patients with node-positive stage IV CRC.
RESULTS: Kaplan-Meier analysis showed that CSS was better in patients with CRC and all the mLNs showing tubular-type carcinoma. In contrast, patients with at least some mLNs showing poorly differentiated-type carcinoma had poor prognosis. Multivariate analysis showed that "all mLNs showing tubular-type carcinoma" was an independent good prognostic factor for CSS in patients with node-positive stage IV CRC. In addition, "at least some mLNs showing poorly differentiated-type carcinoma" was an independent poor prognostic factor for CSS in patients with node-positive stage IV disease.
CONCLUSIONS: The histological type of the mLN may indicate a better or poor prognosis for patients with stage IV CRC.
Treatment according to current guidelines. Often a 7 day course of antibiotics. Initial treatment should be broad spectrum antibiotics and can be narrowed down if a specific pathogen is identified.
Adolescents and young adults who use drugs are at high risk for infection with HIV, STDs and other diseases with similar transmission dynamics. Although several age-appropriate and effective HIV, STD and disease prevention efforts have been identified for young substance abusers, most interventions have been narrow in focus and are generally not structured to readily address changing patterns of drug use among adolescents that place them at risk for infection with these diseases. In this study, we are developing and evaluating an interactive, computer-assisted HIV, STD and disease prevention program for young substance abusers that incorporates effective components of both prevention science and educational technologies. We plan to develop this program with the input from the target population of adolescents and young adults. We also plan to conduct a randomized, controlled trial to evaluate the benefit of including this program in HIV and disease prevention efforts with youth in substance abuse treatment. In so doing, we will evaluate the ability of the program to promote accurate knowledge about HIV and other diseases, promote self-efficacy to reduce risk behavior and change actual rates of risk behavior among young substance abusers. This computer-based program will be designed to promote the increased adoption of effective HIV and disease prevention science for this population. New information about changing patterns of drug use and HIV risk behaviors can be readily incorporated into the program as it becomes available. The program can be easily exported and able to be applied with fidelity. Importantly, the program will be structured such that a therapist or educator may customize the program content for use by various sub-populations of substance-abusing adolescents and young adults. Thus, the program will be able to address risk factors specific to each young drug user. This program may address many of the challenges associated with the current delivery of evidence-based HIV prevention programs to this population.
In people with intellectual disabilities research and policy are often still focused on risks or the prevention of risks. Research on the process of resilience is in its infancy in the care for people with intellectual disabilities. In the current study, applying a guided photovoice procedure, people with intellectual disabilities were asked what helped them to deal with adverse events. Additionally, informants from their social network were asked to reflect on this question. The following sources of resilience were identified: acceptance, autonomy, beautiful memories, perseverance, physical wellbeing, positive emotions, social skills, spirituality, activities, a home and the social network. Our findings provide practical guidelines for clinicians to talk about resilience with people with intellectual disabilities. Suggestions for future research are made that will contribute to the process of resilience and inclusion of people with intellectual disabilities.
In addition to nutritional counseling, patients will receive two servings of an oral high-calorie-high-protein nutritional liquid supplement enriched in immunonutrients (Impact®). The intervention will start 10-15 days before anticancer treatment initiation and will continue until treatment termination or dropout.
After undergoing phase one of periodontal therapy, patients will be recalled after four weeks for root coverage surgery. NORD group will undergo NORD flap for root coverage. Patients will be followed up after 1 month,6, 12 and 15 months. Patients belonging to thin phenotype will be followed up as separate cohort for period of one year to evaluate phenotype modification.
Teen CBT-I The second of the two treatments with a therapist is similar to CBT-I but adapted for teens. Teens in this treatment condition will similarly have an intake session and 6 treatment sessions. The first session will include an introduction to Sleep Science and Insomnia Treatment. Middle sessions will include Healthy Sleep Habits, Setting a Sleep Schedule, Preparing the Mind and Body for Sleep, and Distinguishing the Sleep Space and Wake Space. The final session will be be centered on maintenance of treatment gains. Treatment will also similarly include visual aids (e.g., slides) to convey didactic or psychoeducational material.
Hepatocellular carcinoma (HCC) is the most common malignant tumor of the liver. Chronic hepatitis B infection is the common etiology for the development of HCC. Transcatheter arterial chemoembolization (TACE) is the traditional method for the palliative management of patients with HCC. Few previous studies had demonstrated that the serum level of anticancer drug from patients treated by TACE was similar to those treated by systemic chemotherapy. Since systemic chemotherapy may have the possibility to influence patient's general defense ability, hepatitis B virus may reactivate after chemotherapy. There is no study to investigate the possibility of TACE in the reactivation of hepatitis B virus. This project will collect 20 patients with HCC caused by hepatitis B who are planned to be treated by TACE. Quantitative determination of viral load in blood will be performed before TACE, the first and the third month after TACE to investigate the influence of TACE on hepatitis B virus replication. This study will not influence the doctor's decision in the management of HCC and the procedure of TACE. The serum used for HBV DNA examination is concomitantly obtained during regular blood sampling for TACE preparation and follow-up of patient. The amount of blood needed for each time HBV DNA examination is less than 10 ml.
BACKGROUND: Social constructs like race can affect how patients are perceived and impact care. This study investigated whether mentions of race in notes for critically ill patients differed according to patients' race.
METHODS: This retrospective cohort study included intensive care unit notes for adults (≥18 years old) admitted to any of 6 intensive care units at University of California, San Francisco, from 2012 through 2020. Notes were linked to National Provider Identifier records to obtain note writer characteristics. Logistic regression analysis with robust SEs clustered on note writers was adjusted for patient-, note- and clinician-level characteristics. Any race or ethnicity mention was the outcome of interest.
RESULTS: Among 5573 patients with 292 457 notes by 9742 unique note writers, 3225 patients (57.9%) self-reported their race as White, 997 (17.9%) as Asian, 860 (15.4%) as Latinx, and 491 (8.8%) as Black. Note writers documented race/ethnicity for 20.8% of Black, 10.9% of Latinx, 9.1% of White, and 4.4% of Asian patients. Black patients were more likely than White patients to have race mentioned in notes (adjusted odds ratio, 2.05 [95% CI, 1.49-2.82]).
CONCLUSIONS: Black patients were more than twice as likely as White patients to have race mentioned in notes. Note language containing information on social constructs has consequences for clinicians and patients reading notes and for algorithms trained on clinical notes.
Methods and systems for automatically determining image characteristics serving as a basis for a diagnosis associated with an image study type. One system includes a server including an electronic processor and an interface for communicating with at least one data source. The electronic processor is configured to receive an image study from the at least one data source over the interface. The image study being of the image study type and including a plurality of images. The electronic processor is also configured to determine an image characteristic for each of the plurality of images and determine whether each of the plurality of images was used to establish a diagnosis. The electronic processor is also configured to store the image characteristic for each of the plurality of images and an indicator of whether each of the plurality of images was used to establish the diagnosis in a data structure.
Bipolar disorder is a serious and chronic illness representing a major health problem with high mortality rates (Colom and Lam, 2005). According to the self-regulation model (Leventhal, Nerenz \& Steel, 1986), patients had some representations of their illness which are cognitive and emotional. Cognitive representations include the set of beliefs built around the illness, its consequences and treatment. Emotional representations are negative emotions generated by the presence of the illness. According to Leventhal et al. (1997), representations are linked to information extracts by patients from society, relatives, experiences. This model has been particularly studied in the context of somatic disorders, but Baines \& Wittkowski (2013) shown that it may also be relevant in patients with mental disorders. In bipolar disorders, first results show that illness representations are related to relapses (Lobban et al., 2013) and to medication adherence (Averous, Charbonnier, Lagouanelle-Simeoni, Prosperi \& Dany, 2018). That's why, we think that this relevant to improve knowledges of the psychological processes that accompany the experience of bipolar disorders. To assess illness representation, we will use both qualitative and quantitative tools. These results could have direct application to clinical practice in psychosocial interventions.
PURPOSE: A cosmetic composition for preventing, improving or treating pimples is provided to enhance suppression effects on pimple cause virus and 5A-reductase. CONSTITUTION: A cosmetic composition for preventing, improving or treating pimples includes Hovenia Dulcis Fruit as active ingredient. The herb is Melissa Officinalis leaf extract, bergamot, Mentha arvensis L. var. piperascens MALINV. leaf or Eclipta prostrate. The herbal extract is extracted as water, C1-C3 of alcohol, and a mixture thereof. The herbal extract is water-soluble component. The herbal extract and Hovenia Dulcis Fruit are contained at the mass rate of 1- 10 : 1-10. The mixing extract has an antibacterial activity towards Propionbacterium acnes, Staphylococus epidermidis or Malassezia furfur. A composition for preventing, improving or treating pimples includes Melissa officinalis extract, Bergamot extract, Ecliptae Herba extract and hovenia dulcis as the active ingredient. [Reference numerals] (AA) S.epidermidis; (BB) Growth rate(%); (CC) Sample
Patients receive ixazomib citrate PO on days 1, 8, and 15 and idasanutlin PO QD on days 1-5 every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive dexamethasone PO on days 1, 8, 15, and 22 every 28 days for 12 courses at the discretion of the treating physician.
Methods, systems, and computer-readable media are disclosed herein for providing objective electronic medical record (EMR) system adoption analysis. In an aspect, a subjective input and an objective input is received by a user via a user computing device. The subjective input is comprised of at least one of knowledge assessment related to an EMR system, an attitude assessment related to the EMR system, or a practice assessment related to the EMR system. The objective input is comprised of demographic data related to the user of the EMR system. A score is then calculated for the objective and subjective input, wherein calculating the score comprises applying a weight to the objective and the subjective input to determine one or more of a knowledge score, an attitude score, or a practice score. It is determined that at least one of the knowledge score, attitude score, or practice score, is below at least one predetermined threshold. And, responsive to determining this, an intervention module associated with at least one of the knowledge score, attitude score, or practice score, is automatically transmitted to the user.
Patients taking phenytoin should be advised of the importance of adhering strictly to the prescribed dosage regimen, and of informing the physician of any clinical condition in which it is not possible to take the drug orally as prescribed, e.g., surgery, etc.

Patients should also be cautioned on the use of other drugs or alcoholic beverages without first seeking the physician's advice.

Patients should be instructed to call their physician if skin rash develops. The importance of good dental hygiene should be stressed in order to minimize the development of gingival hyperplasia and its complications. Patients, their caregivers, and families should be counseled that AEDs, including phenytoin, may increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.

Patients should be encouraged to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry if they become pregnant. This Registry is collecting information about the safety of antiepileptics drugs during pregnancy. To enroll, patients can call the toll free number 1-888-233-2334 (see PRECAUTIONS: Pregnancy section).

Do not use capsules which are discolored.
The invention relates to the use of monoclonal antibodies specific for respiratory syncytial virus (RSV). Specifically, the invention relates to a monoclonal antibody IgG2A secreted by the cell line of hybridoma 8A4/G9 specifically directed to the M2-1 viral antigen, which is associated with the nucleocapside of the virus. The antibodies can be used for assays for the detection and/or determination of RSV infection. Said antibodies are in the pure state and do not contain any other contaminating biological material. The invention also relates to a method for preventing and treating the infection caused by respiratory syncytial virus (RSV) in a host, comprising the administration of a composition containing the monoclonal antibodies secreted by the 8A4/G9 hybridoma in sufficient doses to prevent the disease.; The antibody can be humanised in order to minimise the possibility of an immune response against same in the patient. In addition, the invention can be used to obtain any pharmaceutical form of the formulation of the monoclonal antibodies secreted by the 8A4/G9 hybridoma which are suitable for the treatment or prevention of the disease caused by RSV. In addition, the invention relates to methods for the diagnosis and detection of viral antigens of RSV in biological samples, using the monoclonal antibodies produced and secreted by cells of the 8A4/G9 hybridoma.
Circular RNAs (circRNAs) have been confirmed to mediate infantile pneumonia development. In this, we investigated the role and new mechanism of circ_0035292 regulating infantile pneumonia progression. Lipopolysaccharide (LPS)-treated WI-38 cells were used to mimic infantile pneumonia cell injury models. Quantitative real-time PCR was used to measure circ_0035292, microRNA (miR)-494-3p and toll-like receptor 4 (TLR4). Cell proliferation and apoptosis were assessed by MTT assay, EdU assay, and flow cytometry. Protein expression was tested using western blot analysis. Inflammation and oxidative stress were evaluated by measuring IL-6, IL-1β, MDA and SOD levels using ELISA assay and corresponding kits. RNA interaction was confirmed by dual-luciferase reporter assay and RIP assay. Circ_0035292 had elevated expression in infantile pneumonia patients and LPS-induced WI-38 cells. Silenced circ_0035292 could enhance WI-38 cell proliferation, while suppress apoptosis, inflammation and oxidative stress under LPS treatment. Mechanically, circ_0035292 targeted miR-494-3p to positively regulate TLR4. The rescue experiments indicated that miR-494-3p inhibitor abolished the function of circ_0035292 knockdown, and TLR4 overexpression reversed the inhibitory effect of miR-494-3p on LPS-induced WI-38 cell injury. Circ_0035292 might be a potential target for infantile pneumonia treatment, which knockdown could relieve LPS-induced cell injury via the regulation of miR-494-3p/TLR4 axis.
The invention discloses a target for regulating intestinal mucosa homeostasis or inflammatory bowel disease of mammals and application thereof. The target is Fas related death domain FADD protein, and the sequence of the FADD protein is an amino acid sequence shown in SEQ ID No. 1. The method is realized by simulating the expression of protein corresponding to FADD non-phosphorylated gene, and the sequence of the gene is the nucleotide sequence shown in SEQ ID No. 2. The protein corresponding to the gene simulating the non-phosphorylation of the FADD is obtained by mutating the 194 th serine of the wild-type human FADD protein to alanine, or mutating the 191 th serine of the mouse FADD protein to alanine. The mock non-phosphorylated FADD (S191A) mice of the present invention exhibited more severe intestinal inflammation.
The use of collagen as a biomedical implant raises safety issues towards viruses and prions. The physicochemical changes and the in vitro and in vivo biocompatibility of collagen treated with heat, and by formic acid (FA), trifluoroacetic acid (TFA), tetrafluoroethanol (TFE) and hexafluoroiso-propanol (HFIP) were investigated. FA and TFA resulted in extensive depurination of nucleic acids while HFIP and TFE did so to a lesser degree.  The molecules of FA, and most importantly of TFA, remained within collagen.  Although these two acids induced modification in the secondary structure of collagen, resistance to collagenase was not affected and, in vitro, cell growth was not impaired. Severe dehydrothermal treatment, for example 110 ~C  for 1-3 days under high vacuum, also succeeded in removing completely nucleic acids. Since this treatment also leads to slight cross-linking, it could be advantageously used to eliminate prion and to stabilize gelatin products.  Finally, prolonged treatment with TFA provides a transparent collagen, which transparency is further enhanced by adding glycosaminoglycans or proteoglycans, particularly hyaluronic acid. All the above treatments could offer a safe and biocompatible collagen-derived material for diverse biomedical uses, by providing a virus or prion-free product.
A vaccine for immunising a vertebrate against a protozoal disease comprises an antigen preparation of protozoal origin together with a saponin preparation.  The vaccine may contain appropriate pharmaceutical excipients and may be sterile.  The antigen preparation can be obtained from the causative protozoa, or from a morphological form other than that occurring in the vertebrate host. Antigen preparations for vaccines against disease caused by Trypanosoma spp. may be obtained from other species of protozoal flagellate non-pathogenic to the vertebrate species to be immunised. The antigen preparation can be obtained from protozoal cells grown in culture medium and, in many instances, from the surrounding medium. The cellular antigen preparation may be produced by killing the protozoal cells using conventional techniques.  The medium itself may be used as an extra-cellular antigen preparation, or the antigenic material may be isolated therefrom.
The present invention relates to the technical field of structure grease. Disclosed are a lipid soluble caffeic acid fatty acid structure grease, a preparation method therefor, and application thereof. The chemical name of the lipid soluble caffeic acid fatty acid structure grease of the present invention is monocaffeoyl monooleoyl glyceride, more specifically, monocaffeoyl monooleoyl diacylglycerol. The structure is shown as follows: formula (I) and formula (II). R = linoleoyl, octadecatrienoyl, or palmitoleoyl. According to the present invention, non-solvent systems are used twice to promote the exchange reaction of ethyl caffeate and glyceride to prepare 1-monocaffeoyl glyceride, then conducting exchange reaction with fatty acid to prepare corresponding diglyceride to achieve the preparation of a lipid soluble caffeic acid derivative. Three novel phenololipoids are acquired as functional greases. The novel phenololipoids have multiple biological activity of caffeic acid, have strong anti-oxidant activity in water soluble or alcohol soluble systems and overcomes the shortcoming of bad lipid solubility of caffeic acid. Also, the grease can be used as anti-oxidant in the fields of food (especially greasy products), cosmetics, and the like, and has great economic and social value.
This is a multicenter, parallel group, randomized, double-blind, placebo-controlled, trial with clinical endpoint comparing Podofilox Topical Gel 0.5% to Condylox® Gel 0.5% and a matching placebo. The study will be conducted among adult male and female patients with external anogenital warts. The Investigator will assess vital signs and perform physical examination identifying any clinically significant abnormalities. Laboratory samples will be collected, including HIV, Hepatitis B\&C, and urine pregnancy tests (UPT) for women of childbearing potential. The Investigator will confirm the diagnosis of External Anogenital Warts (EAW) and the absence of contraindications specified in the exclusion criterion 4 during the visual examination. The biopsy of skin lesions will be performed per the discretion of the Investigator for microscopic verification of the diagnosis of EAWs if any doubts of the diagnosis.